Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
APPENDIX 4C
Quarter Ended
30 September 2023
An Alternate Future
Alterity Therapeutics Limited
(formerly Prana Biotechnology Limited)
ACN 080 699 065
Appendix 4C – Q1 FY24 Quarterly Cash Flow Report
Highlights:
• Participant screening closed for ATH434-201 Phase 2 study
• Independent Data Monitoring Committee recommended the ATH434-201 Phase 2 study
continue as planned
• Received A$4.74M cash refund under the Australian R&DTI Scheme
• Data presentations from Alterity’s bioMUSE natural history study of Multiple System Atrophy
were delivered at the International Congress of Parkinson’s Disease and Movement Disorders
• New composition of matter patent granted by European Patent Office
• Cash balance on 30 September 2023 of A$16.7M
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 October 2023. Alterity Therapeutics
Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company
dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its
Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending
30 September 2023 (Q1 FY24).
“Alterity had a great start to the 2024 financial year with significant developments in the first quarter,”
said David Stamler, M.D., Chief Executive Officer of Alterity. “Our two Phase 2 clinical trials in Multiple
System Atrophy (MSA) are on track as we look to develop a new treatment for this devastating rare
disease. Of note, we have closed screening in the ATH434-201 study and expect to close enrollment
imminently. In addition, an independent Data Monitoring Committee (DMC) recommended that the
trial continue as planned and they expressed no concerns about safety. These events are important
milestones in the development of ATH434 for the treatment of early-stage MSA.”
“While the ATH434-201 trial is evaluating individuals with early-stage MSA, we are also conducting a
second Phase 2 trial in individuals with more advanced disease. This open label, biomarker study will
give us the opportunity to assess the effect of ATH434 in multiple populations and we also expect it
to provide preliminary data in the first cohort of participants in the first half of next year,” concluded
Dr. Stamler.
The Company’s cash position on 30 September 2023 was A$16.7M with operating cash outflows for
the quarter of A$4.1M, offset by a refund of $4.7M from the Australian Taxation Office under the
Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme for eligible
activities conducted during the financial year ending 30 June 2022.
Operational Activities
ATH434–201: Randomized, Double-Blind Phase 2 Clinical Trial in MSA
Today, Alterity announced that screening has closed for its ATH434-201 Phase 2 clinical trial, an
important step to completing enrollment in the study. On 26 July, Alterity announced that an
independent DMC recommended the trial continue as planned. The DMC conducted a prespecified
review of unblinded clinical data from an initial cohort of study participants. The DMC expressed no
concerns about safety and recommended that the study continue without modification.
This randomized, double blind, placebo controlled clinical trial continues to progress with early-stage
MSA participants enrolled in seven countries globally. The trial has been well received by the study
investigators as they implement Alterity’s state of the art methods to diagnose, treat and track the
disease.
ATH434–202: Open-label, Biomarker Phase 2 Clinical Trial in MSA
The ATH434-202 trial is enrolling according to plan. The study is assessing the effect of ATH434
treatment on neuroimaging and protein biomarkers to evaluate target engagement, in addition to
clinical measures, safety, and pharmacokinetics. The primary objective of this study is to evaluate the
impact of 12 months treatment with ATH434 on brain iron by MRI in a more advanced patient
population than is being studied in Alterity’s double blind Phase 2 trial. Preliminary data from the first
cohort in this study is expected in the first half of 2024.
bioMUSE Natural History Study
Alterity’s bioMUSE natural history study continues to produce meaningful data to address the need
for novel approaches to the evaluation of individuals with MSA. The diagnosis of early MSA can be
challenging as individuals often present similarly to Parkinson’s disease. On 31 August, presentations
from bioMUSE were delivered at the prominent International Congress of Parkinson’s Disease and
Movement Disorders (MDS). The presentations addressed the importance of incorporating
biomarkers in diagnosis of MSA and support the need for a timely and accurate diagnosis to ensure
that the right treatment can be delivered to patients.
Findings from the bioMUSE study are being incorporated into the Company’s Phase 2 studies.
Alterity’s unique protocol designs help to ensure they are enrolling the right patient population with
confirmed MSA, thus giving ATH434 the best chance at success. Based on the collaboration with
clinical and neuroimaging experts from Vanderbilt University Medical Center in the U.S., Alterity is in
a unique position to implement this strategy in its development programs.
Composition of Matter Patent Granted in Europe
The European Patent Office granted Alterity a new composition of matter patent. The patent secures
broad protection over a new class of iron chaperone drug candidates for treating major
neurodegenerative diseases. It is well established that excess iron in the brain is implicated in the
pathology of many important neurodegenerative diseases, including Alzheimer’s and Parkinson’s
diseasesi.
The composition of matter patent, entitled, “Compounds for and Methods of Treating Diseases”,
Patent No. 3938364 covers more than 150 novel pharmaceutical compositions that are designed to
redistribute the excess iron implicated in neurodegenerative diseases. The patent will confer on
Alterity 20 years of exclusivity over the compounds claimed in the patent, thus providing a strong basis
for drug development and commercialization.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the
potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform
generating patentable chemical compounds to intercede in disease processes. The Company is based
in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the
Company’s web site at www.alteritytherapeutics.com.
END
Authorisation & Additional information
This announcement was authorised by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 4 5064 8064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities
Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such
forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes,"
"could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the
exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forwardlooking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC,
including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited
to the following: statements relating to the Company's drug development program, including, but not limited
to the initiation, progress and outcomes of clinical trials of the Company's drug development program,
including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements
involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the
difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the
Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure
additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of
the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products
coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or
trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the
Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently
available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly
update any forward-looking statement, whether written or oral, that may be made from time to time, whether
as a result of new information, future developments or otherwise.
i
Dusek, P. et al. Cerebral Iron Deposition in Neurodegeneration. Biomolecules 2022, 12, 714.
https://doi.org/10.3390/biom12050714.
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
Alterity Therapeutics Limited
ABN
Quarter ended (“current quarter”)
37 080 699 065
30 September 2023
Consolidated statement of cash flows
Current quarter
$A’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (3
months)
$A’000
-
-
(2,951)
(2,951)
-
-
(45)
(45)
-
-
(e) staff costs
(830)
(830)
(f)
(369)
(369)
-
-
82
82
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
-
-
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
4,679
4,679
1.8
Other (provide details if material)
(17)
(17)
1.9
Net cash from / (used in) operating
activities
549
549
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(4)
(4)
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
(c) property, plant and equipment
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$A’000
Year to date (3
months)
$A’000
Proceeds from disposal of:
(a) entities
-
-
(b) businesses
-
-
(c) property, plant and equipment
-
-
(d) investments
-
-
(e) intellectual property
-
-
(f)
-
-
other non-current assets
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
(4)
(4)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
-
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
1
1
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
(18)
(18)
3.10
Net cash from / (used in) financing
activities
(17)
(17)
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
15,773
15,773
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
549
549
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(4)
(4)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (3
months)
$A’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(17)
(17)
4.5
Effect of movement in exchange rates on
cash held
408
408
4.6
Cash and cash equivalents at end of
period
16,709
16,709
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
16,709
15,773
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
16,709
15,773
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
131
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
$A'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
The amount at 6.1 includes payment of director’s fees and salaries and consulting fees, excluding GST where
applicable.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$A’000
Amount drawn at
quarter end
$A’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(4,130)*
8.2
Cash and cash equivalents at quarter end (item 4.6)
16,709
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
-
$A’000
16,709
4.0
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
*The company has excluded the R&D tax incentive of $4,679 (item 1.7) from the calculation of ‘Net cash
from / (used in) operating activities’ (item 8.1) to better reflect the ‘Estimated quarters of funding available’
(item 8.5).
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
30 October 2023
Authorised by: Phillip Hains – Company Secretary
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover